14-3-3 - A Novel Regulator of the OncogenicWnt Signaling Pathway

5^th World Congress on Cancer Therapy

September 28-30, 2015 Atlanta, USA

Rina Rosin-Arbesfeld, Shiri Dovrat, AlonaZilberberg, LitalLahav and Michal Caspi

Posters-Accepted Abstracts: J Cancer Sci Ther

Abstract :

Aberrant activation of the canonical Wnt signal transduction pathway is involved in a large number of humandiseases and s implicated in most cases of colorectal cancer (CRC).�?²-catenin, the key effector protein of the canonical Wnt pathway,induces expression of Wnt target genes by binding to the T-cell factor/lymphoid enhancer factor (TCF/LEF) nuclear proteins. We have recently found that members of the 14-3-3 protein familyare tightly involved in regulation of the Wnt pathway. We will provide evidence showing that 14-3-3 binds disheveled (Dvl) and glycogen synthase 3�?² (GSK-3�?²) to activate the Wnt signal. Importantly, 14-3-3 and �?²-catenin form â�?�?bleb-likeâ�? structures and are secreted via extracellular vesicles to induce Wnt signaling activity in target cells. Our data suggest a novel way of transducing the oncogenic Wnt signal in which �?²-catenin is regulated by 14-3-3 through the formation of extracellular â�?�?oncosomesâ�? that contain both the 14-3-3 and �?²-catenin proteins.

Biography :

Email: arina@post.tau.ac.il